Navigation Links
Resverlogix Completes Dosing for ASSERT Trial
Date:5/12/2010

pare the dose and time response relationship for ApoA-I as well as to examine key reverse cholesterol markers involved with HDL functionality.

In related clinical news the parallel Phase 2 ASSURE trial for RVX-208, which announced its first site activation on February 25th, will be reassessing its enrollment procedure. Since the ASSERT trial provides us with data much faster than first anticipated, we can also now apply pertinent findings to the ASSURE trial. In order to expedite enrollment, while continuing our primary patient safety concerns, the ASSURE trial is being voluntarily halted on a temporary basis in order to modify enrollment procedures. "While the ASSERT trial set records for enrollment, the much more intricate ASSURE trial will not for the reason that the inclusion criteria is much more detailed and intensive. ASSURE currently requires a patient must have had a heart attack within the past four weeks. The patient is then required to voluntarily submit to having two invasive Intravascular Ultrasound (IVUS) both at the start and finish of the 90 day drug treatment period. We believe that we can enhance the enrollment procedure by modifying the inclusion criteria. One such option would be to include any patients sent to the Catheter Lab, thus greatly increasing the pool of patients that we would be able to draw from for enrolment in this trial. Patients will also now benefit from any added knowledge that we are about to gain from the successful completion of dosing in the ASSERT trial," stated Donald McCaffrey.

In other news today, Donald J. McCaffrey will be providing an updated corporate and clinical overview at 1:00 pm EDT. A slide presentation will be followed by a question and answer session regarding the impact of the early completion of the ASSERT trial and the enh
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
2. Resverlogix is Presenting at IAS HDL Workshop
3. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Resverlogix Share Option Extension
6. Resverlogix Notice of Conference Call & Webcast
7. /C O R R E C T I O N from Source -- Resverlogix Corp./
8. Industry Leaders Select Resverlogixs RVX-208
9. Resverlogixs Lead Drug Featured in Key Scientific Publication
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... April 17, 2015  Centrillion Technologies, a ... grant from the National Human Genome Research ... Health (NIH). The grant will help fund ... development of breakthrough genomic technologies, including phased ... substrates. Centrillion has been developing this transformative ...
(Date:4/17/2015)...  Guggenheim Securities, the investment banking and capital markets ... William Tanner as a Managing Director and ... start work at Guggenheim in May 2015 in the ... "Bill brings a wealth of biotech experience, in ... highly acclaimed healthcare team," said Matthew Johnson , ...
(Date:4/17/2015)... Madison, WI (PRWEB) April 17, 2015 ... provide sales and marketing support for the powerful ... at the Chemical Genomics Center at the Lankenau ... LCGC’s mission is to measurably improve successful ... to HTS, by offering rare, drug-like libraries available ...
(Date:4/16/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... results on Thursday, April 30, 2015 at 4:00 PM ... host a conference call at 4:30 PM Eastern Time ... outlook for the future. , The conference call will ... homepage and in the Investor Relations section of Cytokinetics’ ...
Breaking Biology Technology:Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3
... up by 48% at EUR958 Million - EBITDA Margin ... the Target Segment of Pharmaceutical Plastics,in South America: Brazilian ... to provisional figures, Gerresheimer AG has just completed,another record ... up by,48.1%; the adjusted Group EBITDA margin reached 19%. ...
... think a lot about "Homeland Security," but one Montana ... home gardeners also serves to keep us safe from ... the Bozeman campus recently received a five-year grant for ... the lab provides an early warning system of biological ...
... manufactured product our clothes, money, appliances, the paint ... cars will be embedded with intelligence, networks of ... dust or an Internet of Things. The world of ... have surveillance systems, biometrics, personal communicators, machine learning and ...
Cached Biology Technology:2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer 22007 Another Record Year in Terms of Sales and Earnings for Gerresheimer 3Montana State University lab gives early warnings about biological invaders 2Montana State University lab gives early warnings about biological invaders 3Supportive devices or unnecessary surveillance? 2
(Date:3/23/2015)... March 23, 2015  In the 2014 fiscal year, ... conviction losses. This figure accounts for a fraction of ... The Nilson Report, exceeds $11 billion globally. The polygraph ... a crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test ...
(Date:3/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces its ... of the products featured in 2015 "I Want That" ... PM EST on the DIY Network.   ... Vegas , site of the 2015 International CES ...
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... 23, 2013) South Dakota School of Mines ... during multiple thermochemical cycles at low temperatures, sparking ... be feasible. Rajesh Shende, Ph.D., and Jan ... Biological Engineering, have been awarded a $299,975 National ...
... Ill. The overuse of nitrogen fertilizers in agriculture ... An international team of scientists aims to lessen ... similar plants boost their nitrogen production, even in areas ... Center of Plant Genomics and Biotechnology at the Technical ...
... pitch by company CEO John R. Lewandowski, who opened with ... one million lives every year with just refrigerator magnets and ... Magazine/CNN online. The team,s product, based on those ... substance that malaria parasites release when digesting red blood cells. ...
Cached Biology News:The future of power? 2Strengthening legumes to tackle fertilizer pollution 2Hand-held device cheaply, quickly diagnosis malaria 2Hand-held device cheaply, quickly diagnosis malaria 3
...
Alexa Fluor 647 anti-mouse Qa-2...
... IS System is ideal for developing single ... This system contains the new, improved, and ... The user can design specific templates for ... has fully integrated graphing and data regression ...
Mouse monoclonal [0.T.81] to Lac1 ( Abpromise for all tested applications). Antigen: Recombinant TrpE fusion protein containing full length E. coli Lac1....
Biology Products: